Astellas Pharma will pay a premium of $8.50 per share in cash to acquire Ocata Therapeutics Inc. (Nasdaq: OCAT) sending the stock price soaring $3.98 to $8.44.
Ocata Therapeutics to be acquired
November 10, 2015 at 13:27 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.